Dr. Alan W. Partin is The Jakurski Family Director of the Brady Urological Institute, Urologist-In-Chief of Johns Hopkins Medicine and professor of Urology, Pathology and Oncology. He is a prostate surgeon and researcher at The Johns Hopkins Hospital and Johns Hopkins University School of Medicine. Dr. Partin is board certified in urology and has an expertise in prostate cancer, urology and urologic surgery.
Dr. Partin earned his undergraduate degree from the University of Mississippi and his medical degree and Ph.D. in pharmacology and molecular systems from Johns Hopkins University School of Medicine, where he also completed residencies in surgery and urology.
Dr. Partin was named a Top MD by Consumers’ Checkbook Magazine in 2013 and was continuously named one of America’s Top Doctors for cancer by Castle Connolly between 2005 and 2014. Castle Connolly also named Dr. Partin a Top Doctor in the Baltimore and Washington-Baltimore areas in 2012 and 2019. Dr. Partin is a member of the American Cancer Society, American Medical Association, American Urological Association, Society for Basic Urologic Research, Society of Endourology, Society of Urologic Oncology, American Association of Genitourinary Surgeons, Clinical Society of Genitourinary Surgeons, and several other professional organizations.
He has served on the advisory council of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, the infonet editorial board, and the prostate cancer advisory board of the American Cancer Society. He has also been the panel chairman of the National Comprehensive Cancer Network and the research council of the American Urological Association, in addition to other positions.
Dr. Partin has contributed to over 600 scientific articles, publications and presentations. His research has earned him the Ambrose Monell Research Award, the David Koch Prostate Cancer Research Award, the American Urological Association Gold-Cystoscope, the Merck Young Investigator Award, and other accolades.
Dr. Partin is credited with creating a set of nomograms widely known as the Partin Tables. These tables are based on accumulated data from thousands of patients who had been treated for prostate cancer and are used to predict the pathologic stage (the cancer stage as determined by a pathologist after surgery) from clinical (pre-surgery) variables. The accurate prediction of pathologic stage can help physicians and patients choose the most appropriate treatments.
Dr. Partin’s laboratories have also investigated many new serum tests, some of which can diagnose prostate cancer, as well as investigated new urine and tissue proteins that may help in further detection and staging of prostate cancer. Dr. Partin has additional research interests in biomarkers for prostate disease, urology and urologic surgery. He is the editor-in-chief of Urology Case Reports and the editor of the Campbell-Walsh urology text.